Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Each year in the United States, more than 22,000 women are diagnosed with ovarian cancer. Understanding new treatments, as well as how and when to access innovative options available through clinical trials, is important in order to achieve the best outcomes.
Ursula Matulonis, MD, is the medical director of the Gynecologic Oncology Program at Dana-Farber Brigham Cancer Center, and one of the leaders of the Institute's Susan F. Smith Center for Women's Cancers.
Dr. Matulonis' research focuses on new treatments for gynecologic malignancies, with a particular emphasis on ovarian cancer. She is the principal investigator for several ovarian cancer clinical trials and serves on the National Comprehensive Cancer Network’s ovarian cancer committee, which sets patient care guidelines for physicians across the country. Dr. Matulonis has received several awards for her dedication and excellence in the field.
New Patient Appointments
For adults: 877-442-3324For children: 888-733-4662
Video Webchat Series
Dana-Farber's Video Webchat Series features the latest in cancer news and information from top doctors and researchers as well as patients and caregivers. View our upcoming and previous webchat topics.